<DOC>
	<DOCNO>NCT02109250</DOCNO>
	<brief_summary>In registry plan include Belgian patient diagnose aggressive symptomatic unresectable locally advanced metastatic Medullary Thyroid Cancer ( MTC ) prescribe Caprelsa® ( vandetanib ) . The characteristic patient receive Caprelsa® ( vandetanib ) describe . Therefore real life data regard demographic characteristic , evolution disease , RET mutation status , treatment , vandetanib , dose duration treatment Caprelsa® ( vandetanib ) time progression death ( applicable ) include .</brief_summary>
	<brief_title>CAPRELSA® REGISTRY : Belgian Registry Evaluate Use Vandetanib ( Caprelsa® ) Current Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>Inclusion criterion The subject population observe registry , must fulfil follow criterion : 1 . Provision subject Informed Consent 2 . Patients diagnose aggressive symptomatic unresectable locally advanced metastatic MTC 3 . Patients already receive prescription vandetanib accordance scientific leaflet fulfil reimbursement criterion vandetanib currently treat treat vandetanib 100 mg 300 mg tablet . The prescription medicinal product clearly separated decision include subject registry . Exclusion criterion Not applicable since patient participate another study take part registry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Medullary Thyroid Cancer ( MTC ) vandetanib caprelsa</keyword>
</DOC>